Laurus Labs – Strong Pharma Momentum, Breakout Retest in Play?

has staged a powerful recovery from its prolonged consolidation phase and is now trading near multi-year highs on the weekly chart. The stock is showing both technical strength and improving sector sentiment in pharma. Technical Structure Clear reversal from ₹350–400 base after long accumulation. Strong breakout above ₹700 triggered momentum expansion. Recent rally pushed price toward ₹1,100 zone. Sharp pullback followed by quick recovery — sign of demand on dips. Trading above short-term EMA, indicating trend continuation. Stochastic RSI rebounding from oversold region — early momentum reset. Key Levels to Watch: Immediate resistance: ₹1,100–1,150. Breakout confirmation above ₹1,150 could open next leg. Immediate support: ₹980–1,000. Strong structural support: ₹850–900 zone. As long as price sustains above ₹900, the broader bullish structure remains intact. Pullbacks toward ₹1,000 may act as consolidation within trend. Fundamental Perspective Strong presence in ARV APIs and formulations. Expansion in CDMO and oncology segments. Margin recovery phase after previous compression cycle. Capacity utilisation improving with operating leverage. Export-driven model benefits from regulated market demand. Risks & Triggers USFDA observations or regulatory delays. Pricing pressure in generic markets. Raw material volatility impacting margins. Laurus Labs appears to be transitioning from recovery phase to expansion phase. Momentum is strong, but sustainability will depend on earnings acceleration and margin improvement.